Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CD4+ T cell–independent DNA vaccination against opportunistic infections
Mingquan Zheng, … , Qiu Zhong, Jay K. Kolls
Mingquan Zheng, … , Qiu Zhong, Jay K. Kolls
Published December 1, 2005
Citation Information: J Clin Invest. 2005;115(12):3536-3544. https://doi.org/10.1172/JCI26306.
View: Text | PDF | Corrigendum
Research Article Virology

CD4+ T cell–independent DNA vaccination against opportunistic infections

  • Text
  • PDF
Abstract

Depletion or dysfunction of CD4+ T lymphocytes profoundly perturbs host defenses and impairs immunogenicity of vaccines. Here, we show that plasmid DNA vaccination with a cassette encoding antigen (OVA) and a second cassette encoding full-length CD40 ligand (CD40L), a molecule expressed on activated CD4+ T lymphocytes and critical for T cell helper function, can elicit significant titers of antigen-specific immunoglobulins in serum and Tc1 CD8+ T cell responses in CD4-deficient mice. To investigate whether this approach leads to CD4+ T cell–independent vaccine protection against a prototypic AIDS-defining infection, Pneumocystis (PC) pneumonia, we used serum from mice vaccinated with PC-pulsed, CD40L-modifed DCs to immunoprecipitate PC antigens. Kexin, a PC antigen identified by this approach, was used in a similar DNA vaccine strategy with or without CD40L. CD4-deficient mice receiving DNA vaccines encoding Kexin and CD40L showed significantly higher anti-PC IgG titers as well as opsonic killing of PC compared with those vaccinated with Kexin alone. Moreover, CD4-depleted, Kexin-vaccinated mice showed a 3-log greater protection in a PC challenge model. Adoptive transfer of CD19+ cells or IgG to SCID mice conferred protection against PC challenge, indicating a role of humoral immunity in the protection. The results of these studies show promise for CD4-independent vaccination against HIV-related or other opportunistic pathogens.

Authors

Mingquan Zheng, Alistair J. Ramsay, Myles B. Robichaux, Karen A. Norris, Corrine Kliment, Christopher Crowe, Rekha R. Rapaka, Chad Steele, Florencia McAllister, Judd E. Shellito, Luis Marrero, Paul Schwarzenberger, Qiu Zhong, Jay K. Kolls

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
Functionality and antigen specificity of serum after pKexin/CD40L vaccin...
Functionality and antigen specificity of serum after pKexin/CD40L vaccination in mice. (A) Opsonic activity of serum after DNA immunization with control, pKexin, or pKexin/CD40L vectors. (B) Passive transfer of serum or CD19+ splenocytes confers protection against a PC challenge in SCID mice. n = 4–6. All data are mean values ± SEM. *P < 0.05, **P < 0.01 compared with control. (C) Representative Western blot analysis of serum after Kexin vaccination against sonicated PC antigen. Neither naive serum nor serum from CD4-depleted mice with active PC infection gave any activity on Western blotting. Serum from mice undergoing 3 rounds of pKexin/CD40L vaccination (far right 2 lanes) reacted with a 105- and 55-kDa protein. (D) Representative immunofluorescent staining of mouse and monkey PC with anti-Kexin serum.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts